Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$22.95 USD
+0.61 (2.73%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $22.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About Return on Equity (TTM)
Apellis Pharmaceuticals, Inc.'s return on equity, or ROE, is -108.68% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that APLS has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
APLS 22.95 +0.61(2.73%)
Will APLS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
Repligen (RGEN) Lags Q2 Earnings Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
Other News for APLS
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Apellis (APLS) Price Target Raised as Market Stabilizes
RBC Capital Raises Price Target for Apellis Pharmaceuticals (APLS) | APLS Stock News
Raymond James Adjusts Price Target for Apellis (APLS) After Q2 Earnings